Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index; 3 of the 33 sources its claims cite were checked for support.
Abstract
Background: The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database. Patients and Methods: Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available. Results: Of 6477 patients with mCRC (mCRC cohort), 238 (3.7%) had KRAS G12C and 2947 (45.5%) had KRAS non-G12C mutations. Treatment patterns were generally comparable across lines of therapy (LOT) in KRAS G12C versus KRAS non-G12C cohorts. Median (95% CI) OS after the first LOT was 16.1 (13.0-19.0) months for the KRAS G12C cohort versus 18.3 (17.2-19.3) months for the KRAS non-G12C cohort, and 19.2 (18.5-19.8) months for the mCRC overall cohort; median (95% CI) rwPFS was 7.4 (6.3-9.5), 9.0 (8.2-9.7), and 9.2 (8.6-9.7) months, respectively. The different KRAS non-G12C mutations examined did not affect clinical outcomes. Median OS and rwPFS for all cohorts declined with each subsequent LOT. Conclusions: Patients with KRAS p.G12C-mutant mCRC have poor treatment outcomes, and outcomes appear numerically worse than for those without this mutation, indicating potential prognostic implications for KRAS p.G12C mutations and an unmet medical need in this population.
Overview
CoChat Summary
TL;DR
In a large US real-world clinical-genomic database, patients with KRAS p.G12C-mutant metastatic colorectal cancer had numerically shorter overall survival and real-world progression-free survival than patients with other KRAS mutations or the overall mCRC cohort. Treatment patterns were generally comparable across lines of therapy, suggesting potential prognostic implications and an unmet need for KRAS p.G12C-mutant mCRC.
Key findings
- Among 6477 patients with mCRC, 238 (3.7%) had KRAS p.G12C and 2947 (45.5%) had KRAS non-G12C mutations.
- After first-line therapy, median OS was 16.1 months (95% CI 13.0–19.0) for KRAS G12C, 18.3 months (17.2–19.3) for KRAS non-G12C, and 19.2 months (18.5–19.8) for the overall mCRC cohort; median rwPFS was 7.4 months (6.3–9.5), 9.0 months (8.2–9.7), and 9.2 months (8.6–9.7), respectively.
- Median OS and rwPFS declined with each subsequent line of therapy in all cohorts; for KRAS G12C, median OS after first, second, third, and fourth LOT was 16.1, 9.7, 7.2, and 5.2 months, and median rwPFS was 7.4, 4.6, 2.1, and 3.0 months.
- Treatment patterns were generally comparable across lines of therapy between KRAS G12C and KRAS non-G12C cohorts; the different KRAS non-G12C mutations examined did not appear to affect clinical outcomes.
Methods
- Retrospective study of adults (≥18 years) with mCRC diagnosed between January 1, 2011, and March 31, 2020, using the US-based de-identified Flatiron Health–Foundation Medicine clinical-genomic database, with follow-up through September 2020.
- Patients were assigned to KRAS p.G12C, KRAS non-G12C, RAS/BRAF wild-type, overall mCRC, and selected subgroup cohorts (BRAF V600E, KRAS G12D, G12V, G13D) based on comprehensive genomic profiling of >300 cancer-related genes.
- Analyses were descriptive with no formal hypothesis testing; OS and rwPFS were estimated by Kaplan-Meier methods, with delayed-entry statistics used to address immortal time bias.
Limitations
- The authors state that median age was 60 years, slightly younger than reported elsewhere (~65 years), and the percentage of Black patients was lower than expected; the database also lacks information such as the proportion of patients who had metastasectomy.
- The authors state that results may not be generalizable to patients outside the US, treated at academic centers, or who did not undergo genomic sequencing or were sequenced by different methodologies; rwPFS differs from clinical trial PFS and may not be comparable to trial outcomes.
- Evident from the text: analyses were descriptive without formal hypothesis testing, no missing data were imputed, and rwPFS relied on physician evaluation abstracted from EHRs, likely based on less frequent and less systematic assessments than RECIST in clinical trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
1 Valid · 0 Not valid · 20 Not checked · 46 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Introduction
What the sources say
- Partly supportedcites [4] Modest, 2016, Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group, Ann Oncol sourceExperimental — accuracy not yet measured
Our copy supports the OS half of the claim: the Abstract (Results) and the 'prognostic role of single RAS mutation variants' section report that the KRAS G12C variant (n = 28) correlated with inferior OS versus unmutated tumors (multivariate HR 2.26, 95% CI 1.25-4.1, P = 0.001), and the Discussion concludes 'G12C being associated with shorter OS when compared with patients with non-mutated tumors'. It does not support the PFS half: the forest-plot data (Figures 2C/D, p. 1749 ff.) give G12C vs wild-type PFS HR 1.28 (0.7-2.35), P = 0.95, and median PFS for G12C was 10.1 (6.4-13.8) months versus 10.3 (9.7-10.8) months for non-mutated tumors, i.e. longer than G13D (8.8), G12S (9.3), G12V (9.5) and G12A (9.8). The 'compared to other KRAS mutations' element is likewise not established as a finding here: the paper only describes heterogeneous outcome across exon 2 variants against wild type, without a direct G12C-versus-other-variant comparison, so the claim overstates this source on PFS and on the variant-to-contrast. (LLM, conf=0.82)
- Partly supportedcites [5] Henry, 2021, Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer, JCO Precis Oncol sourceExperimental — accuracy not yet measured
Our copy supports the OS-versus-other-KRAS-mutation part: the Results state that patients with KRAS p.G12C had shorter OS than an internal cohort of 720 KRAS nonG12C patients (21.2 v 31.6 months, P = .003), and the Abstract/Conclusion repeat that OS was worse in G12C versus KRAS nonG12C. However, PFS is reported only descriptively within the G12C cohort across first-, second- and third-line chemotherapy (6.4, 3.9, 3.0 months) with no comparator arm, so a PFS disadvantage relative to other KRAS mutations is not attributed by this paper. The additional comparison 'as well as KRAS wild-type tumors' is not supported: the only wild-type comparison in our copy is the comutation analysis (APC, BRAF, TP53 co-occurrence vs KRASWT), with no survival comparison against KRAS wild-type; the Methods state OS 'data were compared with patients with KRAS nonG12C mutations.' (LLM, conf=0.82)
- Partly supportedcites [6] Jones, 2017, Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer, Br J Cancer sourceExperimental — accuracy not yet measured
Our copy supports the OS half of the claim: the Results (Overall survival) and Discussion report p.G12C independently associated with worse overall survival versus KRAS wild-type (univariate HR 2.21, 95% CI 1.15–4.25, P=0.01; median 24.9 vs 35.1 months), and the Discussion states that other codon 12 mutations and codon 13/61 mutations did not impact survival, implying p.G12C is worse than other KRAS mutations (though comparisons were made against wild type, not head-to-head between mutants). The PFS component is not supported: no passage of our copy reports progression-free survival for p.G12C — the Statistical analysis (Methods) lists only overall and disease-free survival as endpoints, and no DFS/PFS result for individual codon 12 point mutations appears. The claim is also stated generally, whereas the cohort is specifically advanced and recurrent/metastatic colorectal cancer (n=392). (LLM, conf=0.80)
- Not checked yetcites [7] Schirripa, 2020, KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population, Clin Colorectal Cancer source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Median OS and rwPFS for all cohorts declined with each subsequent LOT.”
- Also stated in: § Conclusions · plain
“OS and rwPFS further decreased in all cohorts after second, third, and fourth lines of therapy.”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Abstract > Results
plainstates an associationn = 6,477- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Conclusions · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and all numerically longer than the rwPFS observed for the KRAS G12C cohort after the first LOT.”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The different KRAS non-G12C mutations examined did not affect clinical outcomes.”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 4565 patients with mCRC assessed for OS after the first LOT, 308 (6.7%) had BRAF V600E mutations (BRAF V600E subgroup).”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Results
plainn = 4,565- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 67 claims and to verify the 30 references still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Real-world studies of treatment outcomes in KRAS G12C-mutated metastatic colorectal cancer have reported mixed results; some describe a negative association with prognosis, while others report no difference. 8-13”
From Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“KRAS mutations have historically been considered to be “undruggable,” and retrospective series of clinical data suggest that the presence of the KRAS G12C allele is associated with worse survival outcomes than other KRAS mutations in patients with colorectal cancer.12,17”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [28]
In the citing paper
“KRAS G12C mutation occurs in about 4% of colorectal cancers [40].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [40]
In the citing paper
“However, it should be noted that these trials included a molecularly unselected population, while this study only includes patients with KRASG12C-mutated colorectal cancer, a population with a generally worse prognosis (26).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [26]
In the citing paper
“In contrast, 4 recent studies from Japan, US, and China reported poorer survival rates and significantly inferior PFS in patients with KRAS G12C than in those with other KRASm.69,78-80”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [69]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Abstract > Results
“Median OS and rwPFS for all cohorts declined with each subsequent LOT.”
§ Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer > Results
“The median (95% CI) rwPFS in the KRAS G12C cohort was 7.4 (6.3-9.5), 4.6 (2.6-5.5), 2.1 (1.7-4.1), and 3.0 (1.9-4.3) months after the first, second, third, and fourth LOT, respectively”
Citations
Cites
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696 · cited 1×
“Age at metastatic diagnosis, median (range), y 59 (30-84) 60 (20-85) 58 (22-85) 60 (18-85)”
Bailey, C. E., Hu, C.-Y., You, Y. N., Bednarski, B. K., Rodriguez-Bigas, M. A., Skibber, J. M., Cantor, S. B., & Chang, G. J. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2014.1756 · Cited by 1,077 · cited 1×
“Age at metastatic diagnosis, median (range), y 59 (30-84) 60 (20-85) 58 (22-85) 60 (18-85)”
Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., et al. (2019) · JAMA · doi:10.1001/jama.2019.3241 · Cited by 549
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Timar, J., & Kashofer, K. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09915-5 · Cited by 334
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
The KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 219 · cited 1×
“Age at metastatic diagnosis, median (range), y 59 (30-84) 60 (20-85) 58 (22-85) 60 (18-85)”
Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type
Nassar, A. H., Adib, E., & Kwiatkowski, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030638 · Cited by 210
Zhang, Q., Gossai, A., Monroe, S., Nussbaum, N. C., & Parrinello, C. M. (2021) · Health Services Research · doi:10.1111/1475-6773.13669 · Cited by 169
Research works printed but not linked: 1
- American Cancer Society., 2019, Cancer Facts & Figures for African Americans 2019-2021
Cited by
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Self-citationYaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139
“However, it should be noted that these trials included a molecularly unselected population, while this study only includes patients with KRAS G12C -mutated colorectal cancer, a population with a generally worse prognosis (26).”
Self-citationUpdate on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“KRAS G12C mutation occurs in about 4% of colorectal cancers [40].”
BackgroundKuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02717-6 · Cited by 103
Self-citationUnveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 102
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Ros, J., Vaghi, C., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., García, A., Alcaráz, A., Salvà, F., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063304 · Cited by 62
“Indeed, median overall survival (mOS) among patients with KRAS G12C tumors was 16.1 and 9.7 months in the first and second line, whereas mOS for those patients with non-G12C KRAS -mutated tumors was 18.3 and 11.4 months in the first and second line, respectively [12,13].”
BackgroundInfluentialStrickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Self-citationTaïeb, J., Sinicrope, F. A., Pederson, L., Lonardi, S., Alberts, S. R., George, T. J., Yothers, G., Cutsem, E. V., Saltz, L. B., Ogino, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.006 · Cited by 57
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
“…results of clinical trials testing novel orally administered KRAS inhibitors targeting KRAS G12C (a mutated form of KRAS harbouring a single glycine-to-cysteine substitution found in approximately 3% of all metastatic CRCs) including but not limited to sotorasib, adagrasib and divarasib 93–99 .”
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
“PIK3CA mutations are less common in patients with KRAS G12C mutations than in patients with KRAS mutations at alternative sites (14, 19).”
BackgroundResultInfluentialTargeting KRASG12C in colorectal cancer: the beginning of a new era
Ciardiello, D., Maiorano, B. A., & Martinelli, E. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100745 · Cited by 42
Current concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 40
Ottaiano, A., Sabbatino, F., Perri, F., Cascella, M., Sirica, R., Patrone, R., Capuozzo, M., Savarese, G., Ianniello, M., Petrillo, N., et al. (2023) · Cancers · doi:10.3390/cancers15143579 · Cited by 25
Rasola, C., Laurent‐Puig, P., André, T., Falcoz, A., Lepage, C., Aparicio, T., Bouché, O., Lièvre, A., Mineur, L., Bennouna, J., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113321 · Cited by 18
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50026-4 · Cited by 17
“Given the lack of treatment options for these patients and their poor prognosis 10 , further therapeutic developments are urgently needed.”
Modest, D. P., Fakih, M., Salvatore, L., Esaki, T., Páez, D., Taïeb, J., Karamouzis, M. V., Ruíz‐García, E., Kim, T. W., Kuboki, Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00352-3 · Cited by 16
Self-citationHerzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 16
Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 15
High, P. C., Liang, Z., Guernsey-Biddle, C., Subramanian, S., Shyu, Y.-M., Aldana, A. M., Toh, Y., & Carmon, K. S. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102363 · Cited by 14
Association of KRAS G12C Status with Age at Onset of Metastatic Colorectal Cancer
Aruquipa, M. P. S., Peixoto, R. D., Jacome, A. A. D. A., Cesar, F., Lorandi, V., & Dienstmann, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46020088 · Cited by 11
“…prognosis in comparison to other KRAS mutations and RAS wild-type tumors, and with the recent development of specific inhibitors, the understanding of this biomarker can be useful to improve the outcomes of EOCRC patients that so far have similar results to the population of 50 years or older [35].”
ResultYildirim, H. C., Gunenc, D., Almuradova, E., Sutcuoglu, O., & Yalcin, S. (2025) · Medicina · doi:10.3390/medicina61030408 · Cited by 10
Kavgacı, G., Akiva, İ., Ozon, Y. H., Berkil, H., Karadayi, H., Dizdar, O., & Yalçın, Ş. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70042 · Cited by 11
“In the United States, Fakih et al. [20] reported that among 6477 mCRC patients, 49.8% had KRAS mutations and 4.5% had NRAS mutations.”
InfluentialMasuishi, T., Strickler, J. H., Kuboki, Y., Fakih, M., Greil, R., Galot, R., Price, T. J., Élez, E., Siena, S., Hippenmeyer, J., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108338 · Cited by 10
“26,27 About two-thirds of the patients in CodeBreaK 101 receiving sotorasib plus panitumumab and FOLFIRI were heavily pretreated (i.e. 2 or ≥ 3 prior treatments).”
Self-citationPrecision oncology for KRASG12C-mutant colorectal cancer
Nicolantonio, F. D., & Bardelli, A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00748-z · Cited by 8
Ugai, S., Yao, Q., Takashima, Y., Zhong, Y., Matsuda, K., Kawamura, H., Imamura, Y., Okadome, K., Mima, K., Arima, K., et al. (2024) · Cancer Science · doi:10.1111/cas.16262 · Cited by 9
“9,19,40 All of these findings as well as results of the current study need to be replicated in multiple independent studies.”
ResultArdito, F., Razionale, F., Campisi, A., Carlino, A., Vellone, M., Vani, S., Larocca, L. M., & Giuliante, F. (2022) · Cancers · doi:10.3390/cancers14184370 · Cited by 6
Toledo, D. C., Jiménez‐Fonseca, P., López, C., Montés, A. F., Muñoz, A. M. L., Rivera, F. V., Alonso, V., Alcaide, J., Salvà, F., Rúa, M. C., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02563-w · Cited by 5
Kavgacı, G., Dızdar, Ö., & Yalçın, Ş. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001587 · Cited by 5
“This mutation is found in approximately 3 – 4% of mCRC cases and is often associated with a poorer prognosis [4].”
BackgroundKRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 7
Self-citationYokoi, R., Mori, T., Hirosawa, K. M., Kondo, R., Taguchi, T., Matsuhashi, N., & Suzuki, K. G. N. (2025) · iScience · doi:10.1016/j.isci.2025.113374 · Cited by 4
“…studies have reported that specific KRAS alleles, such as G12C, are associated with worse outcomes and differential responses to therapy in CRC. 22,23 These challenges underscore the necessity for KRAS-mutation-specific analysis of signaling behavior, which remains insufficiently understood…”
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 5
“14,20,25 Indeed, this fi nding was recently con fi rmed in a Japanese cohort of around 300 patients with KRAS-mutated mCRC, including about 30% of KRASG12D -mutated tumors.”
Pastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 4
Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors
Hoyek, C., Pirozzi, A., Jones, J. M., Rimassa, L., Sonbol, M. B., & Bekaii‐Saab, T. (2024) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2024.20.2.7 · Cited by 3
“13,14 In PDAC, mOS was 16.7 months in KRAS G12C-mutated tumours versus 24.9 months in KRAS non- G12C-mutated tumours.”
InfluentialThe emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment
Kokori, E., Olatunji, G. D., Ogieuhi, I. J., Ajayi, Y. I., Akinmoju, O. D., Akinboade, A., Irumudomon, J. G., Omoworare, O. T., Ezeano, C., Adebayo, Y. A., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02736-y · Cited by 2
Shaykevich, A., Chae, D., Silverman, I., Goel, S., & Maitra, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326029 · Cited by 2
KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets
Martínez‐Pérez, J., & Valladares‐Ayerbes, M. (2024) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-24-48 · Cited by 2
Boby, J. M., Ilerhunmwuwa, N. P., Benny, J. M., Peniche, P. Z., Baytar, D. K., & Sahin, I. H. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2636581 · Cited by 1
The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium
Yang, M. H., Sheth, S., Shui, B., Grabski, I. N., Park, S. S., Galán‐Cobo, A., Irizarry, R. A., Heymach, J. V., Dow, L. E., & Haigis, K. M. (2026) · Oncogene · doi:10.1038/s41388-026-03771-3 · Cited by 1
“Notably, this mutant-speci fi c survival phenotype differs from A.”
Burge, M., Tie, J., Krishnan, T., Roy, A., Chantrill, L., Tebbutt, N. C., Karapetis, C. S., & Price, T. J. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.04.001 · Cited by 1
Molekularpathologie gastrointestinaler Tumoren: Was ist Standard, was kommt?
Bedau, T., & Quaas, A. (2024) · Die Gastroenterologie · doi:10.1007/s11377-024-00777-9
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Liberko, M. (2025) · Onkologie · doi:10.36290/xon.2025.008
Hsieh, M.-C., Rau, K., Liu, K.-W., Chiu, C., Chen, C., Song, L., & Chen, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-36509-y
“In the contrary, KRAS G12Cmut only occurs in up to 4% of patients 23 .”
Khamis, M. M., Lapari, M. S., Alkharabsheh, O., Baral, M. R., Şahin, İ. H., Archwamety, A., Firwana, B., Patel, G. K., Singh, A., Diffalha, S. A., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag219
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117112
“32,33 In addition, patients with acquired RAS MT had shorter OS than those with RAS WT.”
Song, Z., Zhu, L., Liu, Y., Lin, R., Li, X., Luo, Y., Yuan, Y., Shi, H., Zhang, Y., Zhang, B., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00175-0 · Cited by 1
Adico, M. D. W., Coulibaly, T., Dagnogo, D., Savadogo, M., Daramcoum, W. A. M. P., Yao, S., Dago, D. N., Coulibaly, F. H., Snr, A. A. Z., Bayala, B., et al. (2026) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s629435
Metadata
- Authors
- Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S.
- Affiliations
- City Of Hope National Medical Center (US)
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Fakih, Marwan
- Tu, Huakang
- Aggarwal, Shivani
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-04-26
- Volume
- 27
- Issue
- 8
- Pages
- 663-674
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC9355827
- OpenAlex
- W4224981845
- Semantic Scholar
- a11a816f6db3556dd92cede319031e3a6455e2c7
- Cited by
- 43
- References
- 23
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 14 · 2023: 8 · 2022: 5
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- metastatic colorectal cancer, overall survival, progression-free survival, treatment patterns, treatment lines, clinicopathological features, prognostic implications, KRAS inhibitors
- MeSH terms
- Colonic Neoplasms, Humans, Mutation, Prognosis, Rectal Neoplasms, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.